0.023117 0.000000 0.010877 0.000000 0.019342 0.000000 0.000000 0.000000 0.024412 0.00000 0.00000 0.00000 Brinen, L.S. Gillmor, S.A. Fletterick, R.J. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 2 90.00 115.20 90.00 43.258 51.700 45.271 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking H2 O 18.015 WATER non-polymer C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C19 H28 N2 O5 364.436 N-[3-CARBOXY-2-HYDROXY-PROPIONYL]-L-HOMOPHENYLALANYL-AMINO-2-METHYLBUTANE WRR-112 peptide-like C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking To be Published 0353 Crystal Structure of Cruzain bound to WRR-112 University of California, San Francisco (THESIS) Enzyme-ligand Interactions, Inhibition and Specificity 50 80 Chapter 3: X-ray Structures of Complexes of Cruzain with Designed Covalent Inhibitors 1998 US Protein Sci. PRCIEI 0795 0961-8368 6 1603 1611 Structural Determinants of Specificity in the Cysteine Protease Cruzain 1997 UK J.Mol.Biol. JMOBAK 0070 0022-2836 247 251 259 10.1006/jmbi.1994.0137 The Crystal Structure of Cruzain: a Therapeutic Target for Chagas' Disease 1995 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 298 1 IMAGE PLATE 1997-05-18 MARRESEARCH SINGLE WAVELENGTH M x-ray 1 1.5418 1.0 1.5418 ROTATING ANODE RIGAKU RU200 22715.133 CRUZAIN 3.4.22.- CATALYTIC DOMAIN 1 man polymer 364.436 N-[3-CARBOXY-2-HYDROXY-PROPIONYL]-L-HOMOPHENYLALANYL-AMINO-2-METHYLBUTANE 1 syn non-polymer 18.015 water 57 nat water cruzipain, cruzaine no no APAAVDWRARGAVTAVKDQGQCGSCWAFSAIGNVECQWFLAGHPLTNLSEQMLVSCDKTDSGCSGGLMNNAFEWIVQENN GAVYTEDSYPYASGEGISPPCTTSGHTVGATITGHVELPQDEAQIAAWLAVNGPVAVAVDASSWMTYTGGVMTSCVSEQL DHGVLLVGYNDSAAVPYWIIKNSWTTQWGEEGYIRIAKGSNQCLVKEEASSAVVG APAAVDWRARGAVTAVKDQGQCGSCWAFSAIGNVECQWFLAGHPLTNLSEQMLVSCDKTDSGCSGGLMNNAFEWIVQENN GAVYTEDSYPYASGEGISPPCTTSGHTVGATITGHVELPQDEAQIAAWLAVNGPVAVAVDASSWMTYTGGVMTSCVSEQL DHGVLLVGYNDSAAVPYWIIKNSWTTQWGEEGYIRIAKGSNQCLVKEEASSAVVG A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n Trypanosoma Escherichia sample 5693 Trypanosoma cruzi 562 Escherichia coli DH5ALPHA CHEY 1 2.02 38.98 VAPOR DIFFUSION, HANGING DROP 6.5 0.9M NaCitrate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 292K 292 repository Initial release Version format compliance Atomic model Database references Derived calculations Non-polymer description Structure summary Version format compliance 1 0 2003-06-10 1 1 2008-04-27 1 2 2011-07-13 same protein, ZYA inhibitor same protein, ZRA inhibitor same protein, WRR-99 inhibitor same protein, WRR-204 inhibitor same protein, MOR-LEU-HPQ inhibitor RCSB Y RCSB 2000-04-26 REL REL RL2 N-[3-CARBOXY-2-HYDROXY-PROPIONYL]-L-HOMOPHENYLALANYL-AMINO-2-METHYLBUTANE HOH water RL2 IS AN E-64 ANALOG. RL2 WAS N-(3-CARBOXYOXIRANE-2-CARBONYL)-L- HOMOPHENYLALANYL-AMINO-2-METHYLBUTANE BEFORE REACTION WITH THE PROTEASE. DURING REACTION WITH THE PROTEASE, THE EPOXIDE RING OPENS TO FORM N-[3-CARBOXY-2-HYDROXY- PROPIONYL]-L-HOMOPHENYLALANYL-AMINO-2-METHYLBUTANE. THE SG OF CYS 25 IS THEN LINKED TO THE C2 OF RL2 280 AFTER REACTION. THERE IS A STOP CODON AFTER RESIDUE 212. RL2 280 2 RL2 RL2 280 A WAT 1 3 HOH HOH 281 A WAT 2 3 HOH HOH 282 A WAT 3 3 HOH HOH 283 A WAT 4 3 HOH HOH 284 A WAT 5 3 HOH HOH 285 A WAT 6 3 HOH HOH 286 A WAT 7 3 HOH HOH 287 A WAT 8 3 HOH HOH 288 A WAT 9 3 HOH HOH 289 A WAT 10 3 HOH HOH 290 A WAT 11 3 HOH HOH 291 A WAT 12 3 HOH HOH 292 A WAT 13 3 HOH HOH 293 A WAT 14 3 HOH HOH 294 A WAT 15 3 HOH HOH 295 A WAT 16 3 HOH HOH 296 A WAT 17 3 HOH HOH 297 A WAT 18 3 HOH HOH 298 A WAT 19 3 HOH HOH 299 A WAT 20 3 HOH HOH 300 A WAT 21 3 HOH HOH 301 A WAT 22 3 HOH HOH 302 A WAT 23 3 HOH HOH 303 A WAT 24 3 HOH HOH 304 A WAT 25 3 HOH HOH 305 A WAT 26 3 HOH HOH 306 A WAT 27 3 HOH HOH 307 A WAT 28 3 HOH HOH 308 A WAT 29 3 HOH HOH 309 A WAT 30 3 HOH HOH 310 A WAT 31 3 HOH HOH 311 A WAT 32 3 HOH HOH 312 A WAT 33 3 HOH HOH 313 A WAT 34 3 HOH HOH 314 A WAT 35 3 HOH HOH 315 A WAT 36 3 HOH HOH 316 A WAT 37 3 HOH HOH 317 A WAT 38 3 HOH HOH 318 A WAT 39 3 HOH HOH 319 A WAT 40 3 HOH HOH 320 A WAT 41 3 HOH HOH 321 A WAT 42 3 HOH HOH 322 A WAT 43 3 HOH HOH 323 A WAT 44 3 HOH HOH 324 A WAT 45 3 HOH HOH 325 A WAT 46 3 HOH HOH 326 A WAT 47 3 HOH HOH 327 A WAT 48 3 HOH HOH 328 A WAT 49 3 HOH HOH 329 A WAT 50 3 HOH HOH 330 A WAT 51 3 HOH HOH 331 A WAT 52 3 HOH HOH 332 A WAT 53 3 HOH HOH 333 A WAT 54 3 HOH HOH 334 A WAT 55 3 HOH HOH 335 A WAT 56 3 HOH HOH 336 A WAT 57 3 HOH HOH 337 A ALA 1 n 1 ALA 1 A PRO 2 n 2 PRO 2 A ALA 3 n 3 ALA 3 A ALA 4 n 4 ALA 4 A VAL 5 n 5 VAL 5 A ASP 6 n 6 ASP 6 A TRP 7 n 7 TRP 7 A ARG 8 n 8 ARG 8 A ALA 9 n 9 ALA 9 A ARG 10 n 10 ARG 10 A GLY 11 n 11 GLY 11 A ALA 12 n 12 ALA 12 A VAL 13 n 13 VAL 13 A THR 14 n 14 THR 14 A ALA 15 n 15 ALA 15 A VAL 16 n 16 VAL 16 A LYS 17 n 17 LYS 17 A ASP 18 n 18 ASP 18 A GLN 19 n 19 GLN 19 A GLY 20 n 20 GLY 20 A GLN 21 n 21 GLN 21 A CYS 22 n 22 CYS 22 A GLY 23 n 23 GLY 23 A SER 24 n 24 SER 24 A CYS 25 n 25 CYS 25 A TRP 26 n 26 TRP 26 A ALA 27 n 27 ALA 27 A PHE 28 n 28 PHE 28 A SER 29 n 29 SER 29 A ALA 30 n 30 ALA 30 A ILE 31 n 31 ILE 31 A GLY 32 n 32 GLY 32 A ASN 33 n 33 ASN 33 A VAL 34 n 34 VAL 34 A GLU 35 n 35 GLU 35 A CYS 36 n 36 CYS 36 A GLN 37 n 37 GLN 37 A TRP 38 n 38 TRP 38 A PHE 39 n 39 PHE 39 A LEU 40 n 40 LEU 40 A ALA 41 n 41 ALA 41 A GLY 42 n 42 GLY 42 A HIS 43 n 43 HIS 43 A PRO 44 n 44 PRO 44 A LEU 45 n 45 LEU 45 A THR 46 n 46 THR 46 A ASN 47 n 47 ASN 47 A LEU 48 n 48 LEU 48 A SER 49 n 49 SER 49 A GLU 50 n 50 GLU 50 A GLN 51 n 51 GLN 51 A MET 52 n 52 MET 52 A LEU 53 n 53 LEU 53 A VAL 54 n 54 VAL 54 A SER 55 n 55 SER 55 A CYS 56 n 56 CYS 56 A ASP 57 n 57 ASP 57 A LYS 58 n 58 LYS 58 A THR 59 n 59 THR 59 A ASP 60 n 60 ASP 60 A SER 61 n 61 SER 61 A GLY 62 n 62 GLY 62 A CYS 63 n 63 CYS 63 A SER 64 n 64 SER 64 A GLY 65 n 65 GLY 65 A GLY 66 n 66 GLY 66 A LEU 67 n 67 LEU 67 A MET 68 n 68 MET 68 A ASN 69 n 69 ASN 69 A ASN 70 n 70 ASN 70 A ALA 71 n 71 ALA 71 A PHE 72 n 72 PHE 72 A GLU 73 n 73 GLU 73 A TRP 74 n 74 TRP 74 A ILE 75 n 75 ILE 75 A VAL 76 n 76 VAL 76 A GLN 77 n 77 GLN 77 A GLU 78 n 78 GLU 78 A ASN 78 n 79 A ASN 78 A ASN 78 n 80 B ASN 78 A GLY 78 n 81 C GLY 78 A ALA 79 n 82 ALA 79 A VAL 80 n 83 VAL 80 A TYR 81 n 84 TYR 81 A THR 82 n 85 THR 82 A GLU 83 n 86 GLU 83 A ASP 84 n 87 ASP 84 A SER 85 n 88 SER 85 A TYR 86 n 89 TYR 86 A PRO 87 n 90 PRO 87 A TYR 88 n 91 TYR 88 A ALA 89 n 92 ALA 89 A SER 89 n 93 A SER 89 A GLY 89 n 94 B GLY 89 A GLU 89 n 95 C GLU 89 A GLY 90 n 96 GLY 90 A ILE 91 n 97 ILE 91 A SER 92 n 98 SER 92 A PRO 93 n 99 PRO 93 A PRO 94 n 100 PRO 94 A CYS 95 n 101 CYS 95 A THR 96 n 102 THR 96 A THR 97 n 103 THR 97 A SER 98 n 104 SER 98 A GLY 99 n 105 GLY 99 A HIS 100 n 106 HIS 100 A THR 101 n 107 THR 101 A VAL 102 n 108 VAL 102 A GLY 103 n 109 GLY 103 A ALA 105 n 110 ALA 105 A THR 106 n 111 THR 106 A ILE 107 n 112 ILE 107 A THR 108 n 113 THR 108 A GLY 109 n 114 GLY 109 A HIS 110 n 115 HIS 110 A VAL 111 n 116 VAL 111 A GLU 112 n 117 GLU 112 A LEU 113 n 118 LEU 113 A PRO 114 n 119 PRO 114 A GLN 115 n 120 GLN 115 A ASP 116 n 121 ASP 116 A GLU 117 n 122 GLU 117 A ALA 118 n 123 ALA 118 A GLN 119 n 124 GLN 119 A ILE 120 n 125 ILE 120 A ALA 121 n 126 ALA 121 A ALA 122 n 127 ALA 122 A TRP 123 n 128 TRP 123 A LEU 124 n 129 LEU 124 A ALA 125 n 130 ALA 125 A VAL 126 n 131 VAL 126 A ASN 127 n 132 ASN 127 A GLY 128 n 133 GLY 128 A PRO 129 n 134 PRO 129 A VAL 130 n 135 VAL 130 A ALA 131 n 136 ALA 131 A VAL 132 n 137 VAL 132 A ALA 133 n 138 ALA 133 A VAL 134 n 139 VAL 134 A ASP 135 n 140 ASP 135 A ALA 136 n 141 ALA 136 A SER 139 n 142 SER 139 A SER 140 n 143 SER 140 A TRP 141 n 144 TRP 141 A MET 142 n 145 MET 142 A THR 143 n 146 THR 143 A TYR 144 n 147 TYR 144 A THR 145 n 148 THR 145 A GLY 146 n 149 GLY 146 A GLY 147 n 150 GLY 147 A VAL 148 n 151 VAL 148 A MET 149 n 152 MET 149 A THR 151 n 153 THR 151 A SER 152 n 154 SER 152 A CYS 153 n 155 CYS 153 A VAL 154 n 156 VAL 154 A SER 155 n 157 SER 155 A GLU 156 n 158 GLU 156 A GLN 156 n 159 A GLN 156 A LEU 157 n 160 LEU 157 A ASP 158 n 161 ASP 158 A HIS 159 n 162 HIS 159 A GLY 160 n 163 GLY 160 A VAL 161 n 164 VAL 161 A LEU 162 n 165 LEU 162 A LEU 163 n 166 LEU 163 A VAL 164 n 167 VAL 164 A GLY 165 n 168 GLY 165 A TYR 166 n 169 TYR 166 A ASN 167 n 170 ASN 167 A ASP 167 n 171 A ASP 167 A SER 167 n 172 B SER 167 A ALA 167 n 173 C ALA 167 A ALA 167 n 174 D ALA 167 A VAL 168 n 175 VAL 168 A PRO 169 n 176 PRO 169 A TYR 170 n 177 TYR 170 A TRP 171 n 178 TRP 171 A ILE 172 n 179 ILE 172 A ILE 173 n 180 ILE 173 A LYS 174 n 181 LYS 174 A ASN 175 n 182 ASN 175 A SER 176 n 183 SER 176 A TRP 177 n 184 TRP 177 A THR 178 n 185 THR 178 A THR 179 n 186 THR 179 A GLN 180 n 187 GLN 180 A TRP 181 n 188 TRP 181 A GLY 182 n 189 GLY 182 A GLU 183 n 190 GLU 183 A GLU 184 n 191 GLU 184 A GLY 185 n 192 GLY 185 A TYR 186 n 193 TYR 186 A ILE 187 n 194 ILE 187 A ARG 188 n 195 ARG 188 A ILE 189 n 196 ILE 189 A ALA 190 n 197 ALA 190 A LYS 191 n 198 LYS 191 A GLY 192 n 199 GLY 192 A SER 193 n 200 SER 193 A ASN 198 n 201 ASN 198 A GLN 199 n 202 GLN 199 A CYS 200 n 203 CYS 200 A LEU 201 n 204 LEU 201 A VAL 202 n 205 VAL 202 A LYS 203 n 206 LYS 203 A GLU 204 n 207 GLU 204 A GLU 205 n 208 GLU 205 A ALA 206 n 209 ALA 206 A SER 207 n 210 SER 207 A SER 208 n 211 SER 208 A ALA 209 n 212 ALA 209 A VAL 210 n 213 VAL 210 A VAL 211 n 214 VAL 211 A GLY 212 n 215 GLY 212 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N VAL 134 A N VAL 139 A O HIS 159 A O HIS 162 A N TYR 166 A N TYR 169 A O VAL 5 A O VAL 5 A N VAL 134 A N VAL 139 A O HIS 159 A O HIS 162 A N ASN 167 A N ASN 170 A O TYR 170 A O TYR 177 A N ILE 173 A N ILE 180 A O ILE 187 A O ILE 194 A N ALA 190 A N ALA 197 A O MET 149 A O MET 152 A O VAL 80 A O VAL 83 A N GLY 103 A N GLY 109 A N VAL 111 A N VAL 116 A O SER 208 A O SER 211 1 6.76 0.80 106.30 113.06 A A A CD1 CG CD2 TRP TRP TRP 7 7 7 N 1 -6.03 0.80 107.30 101.27 A A A CE2 CD2 CG TRP TRP TRP 7 7 7 N 1 6.13 0.80 106.30 112.43 A A A CD1 CG CD2 TRP TRP TRP 26 26 26 N 1 -5.68 0.80 107.30 101.62 A A A CE2 CD2 CG TRP TRP TRP 26 26 26 N 1 6.89 0.80 106.30 113.19 A A A CD1 CG CD2 TRP TRP TRP 38 38 38 N 1 -6.02 0.80 107.30 101.28 A A A CE2 CD2 CG TRP TRP TRP 38 38 38 N 1 6.06 0.80 106.30 112.36 A A A CD1 CG CD2 TRP TRP TRP 74 74 74 N 1 -5.59 0.80 107.30 101.71 A A A CE2 CD2 CG TRP TRP TRP 74 74 74 N 1 6.38 0.80 106.30 112.68 A A A CD1 CG CD2 TRP TRP TRP 123 123 123 N 1 -8.36 1.30 127.00 118.64 A A A CB CG CD1 TRP TRP TRP 123 123 123 N 1 -5.85 0.80 107.30 101.45 A A A CE2 CD2 CG TRP TRP TRP 123 123 123 N 1 5.96 0.80 106.30 112.26 A A A CD1 CG CD2 TRP TRP TRP 141 141 141 N 1 -5.33 0.80 107.30 101.97 A A A CE2 CD2 CG TRP TRP TRP 141 141 141 N 1 6.37 0.80 106.30 112.67 A A A CD1 CG CD2 TRP TRP TRP 171 171 171 N 1 -5.74 0.80 107.30 101.56 A A A CE2 CD2 CG TRP TRP TRP 171 171 171 N 1 6.24 0.80 106.30 112.54 A A A CD1 CG CD2 TRP TRP TRP 177 177 177 N 1 -5.75 0.80 107.30 101.55 A A A CE2 CD2 CG TRP TRP TRP 177 177 177 N 1 6.16 0.80 106.30 112.46 A A A CD1 CG CD2 TRP TRP TRP 181 181 181 N 1 -5.33 0.80 107.30 101.97 A A A CE2 CD2 CG TRP TRP TRP 181 181 181 N 1 A A NE2 CD2 HIS HIS 43 43 -0.066 0.011 1.373 1.307 N 1 A A NE2 CD2 HIS HIS 110 110 -0.067 0.011 1.373 1.306 N 1 A PRO 2 -5.96 -67.18 1 A THR 178 68.36 171.76 PARAM19SG.PRO TOHP19SG2.PRO PARAM19.SOL TOPH19.SOL INHIB112.TPX EPOX.TPX 10.9 0.00 0.00 0.00 0.00 0.00 0.00 0.206 0.009 0.173 0.18 0.173 2.00 25.00 570 11819 11819 4.8 95.8 RANDOM 10000000.00 0.00 1 RESTRAINED THROUGHOUT 0.0 -3.0 toph19 and param19 0.24 0.19 5.00 0.19 0.16 2.00 25.00 57 1676 26 0 1593 0.012 2.4 25.9 0.94 0.234 0.026 0.209 2.13 82 1790 6 4.4 92.5 5.5 2.0 30.0 1EWM 11831 11831 0 -3.0 0.094 1 6.0 2.75 95.8 0.167 2.00 2.07 1139 1 2.8 91.3 data reduction DENZO data scaling SCALEPACK phasing AMoRE refinement X-PLOR 3.843 CRUZAIN (E.C.3.4.22.-) THE CYSTEINE PROTEASE CRUZAIN BOUND TO WRR-112 1 N N 2 N N 3 N N the biological assembly is the monomer found in the asymmetric unit A ARG 8 A ARG 8 HELX_P A GLY 11 A GLY 11 5 1 4 A SER 24 A SER 24 HELX_P A ALA 41 A ALA 41 1 2 18 A SER 49 A SER 49 HELX_P A ASP 57 A ASP 57 1 3 9 A SER 61 A SER 61 HELX_P A GLY 65 A GLY 65 5 4 5 A ASP 116 A ASP 121 HELX_P A GLY 128 A GLY 133 1 6 13 A SER 140 A SER 143 HELX_P A TYR 144 A TYR 147 5 7 5 A ASN 198 A ASN 201 HELX_P A VAL 202 A VAL 205 5 8 5 disulf 2.035 A CYS 22 A SG CYS 22 1_555 A CYS 63 A SG CYS 63 1_555 disulf 2.017 A CYS 56 A SG CYS 56 1_555 A CYS 95 A SG CYS 101 1_555 disulf 2.025 A CYS 153 A SG CYS 155 1_555 A CYS 200 A SG CYS 203 1_555 covale 1.827 A CYS 25 A SG CYS 25 1_555 A RL2 280 B C2 RL2 1_555 HYDROLASE/HYDROLASE INHIBITOR cruzain, cruzipain, drug design, covalent inhibitor, cysteine protease, HYDROLASE-HYDROLASE INHIBITOR COMPLEX CYSP_TRYCR UNP 1 123 P25779 APAAVDWRARGAVTAVKDQGQCGSCWAFSAIGNVECQWFLAGHPLTNLSEQMLVSCDKTDSGCSGGLMNNAFEWIVQENN GAVYTEDSYPYASGEGISPPCTTSGHTVGATITGHVELPQDEAQIAAWLAVNGPVAVAVDASSWMTYTGGVMTSCVSEQL DHGVLLVGYNDSAAVPYWIIKNSWTTQWGEEGYIRIAKGSNQCLVKEEASSAVVG 123 337 1EWM 1 212 P25779 A 1 1 215 3 5 2 2 anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel parallel anti-parallel anti-parallel A VAL 130 A VAL 135 A VAL 134 A VAL 139 A HIS 159 A HIS 162 A ASN 167 A ASN 170 A ALA 4 A ALA 4 A ASP 6 A ASP 6 A VAL 130 A VAL 135 A VAL 134 A VAL 139 A HIS 159 A HIS 162 A ASN 167 A ASN 170 A TYR 170 A TYR 177 A LYS 174 A LYS 181 A TYR 186 A TYR 193 A ALA 190 A ALA 197 A VAL 148 A VAL 151 A MET 149 A MET 152 A ALA 79 A ALA 82 A TYR 81 A TYR 84 A VAL 102 A VAL 108 A THR 106 A THR 111 A GLY 109 A GLY 114 A GLU 112 A GLU 117 A SER 207 A SER 210 A VAL 210 A VAL 213 BINDING SITE FOR RESIDUE RL2 A 280 Software 11 A GLN 19 A GLN 19 11 1_555 A GLY 23 A GLY 23 11 1_555 A SER 24 A SER 24 11 1_555 A CYS 25 A CYS 25 11 1_555 A TRP 26 A TRP 26 11 1_555 A SER 61 A SER 61 11 1_555 A GLY 65 A GLY 65 11 1_555 A GLY 66 A GLY 66 11 1_555 A MET 68 A MET 68 11 1_555 A ASP 158 A ASP 161 11 1_555 A HIS 159 A HIS 162 11 1_555 4 P 1 21 1